As BAP1 loss has been found to increase both the activity of EZH2 (which is a component of the polycomb repressor complex 2 (PRC-2)) and the levels of trimethylated histone H3 lysine 27 (H3K27me3), a recent study assessed the effects of EZH2 inhibition on MM progression. Here, EZH2 is linked to Miyoshi myopathy.